乳腺瘤异质性的分子基础
1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Advances in experimental medicine and biology
|January 17, 2025
概括
乳腺癌 (BC) 是一种复杂的疾病,具有显著的分子和临床变异. 了解这种异质性,包括遗传因素和亚型特征,对于有效的诊断和治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 病理学 病理学 病理学
背景情况:
- 乳腺癌 (BC) 是一种高度异质的疾病,具有不同的分子,组织学和临床特征.
- 结核癌的复杂性从其早期阶段就显而易见,涉及从前体病变到侵袭性癌的演变.
- 遗传因素和不同的亚型进一步使疾病的局面复杂化.
研究的目的:
- 强调了解乳腺癌异质性在治疗决策中的关键作用.
- 突出遗传性乳腺癌对疾病表型和基因组特征的影响.
- 强调基因型-表型相关性在特殊组织学亚型中对诊断和治疗的重要性.
主要方法:
- 关于乳腺癌异质性的当前文献综述.
- 分析乳腺癌的分子,组织学和临床变异.
- 检查遗传性乳腺癌遗传学及其对表型的影响.
- 研究特定亚型的代谢需求和免疫微环境.
- 在特殊的组织学乳腺癌亚型中的基因型和表型的相关性.
主要成果:
- 乳腺癌的异质性在分子,组织学和临床水平上是显而易见的,即使在早期阶段.
- 对受体状态和临床亚型的动态评估是治疗决策的关键.
- 遗传性乳腺癌易感基因有助于形成不同的表型和基因组特征.
- 不同的乳腺癌亚型表现出独特的代谢和免疫微环境特征.
- 特殊组织学亚型中的基因型-表型相关性指导诊断和治疗策略.
结论:
- 彻底了解乳腺癌异质性对于明智的诊断和治疗方法至关重要.
- 识别各种各样的亚型,遗传影响和分子变异对于乳腺癌的个性化医学至关重要.
- 动态评估和理解遗传-表型联系对于优化乳腺癌患者护理至关重要.
相关概念视频
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancers Originate from Somatic Mutations in a Single Cell
11.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.5K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K


